Akebia Therapeutics (AKBA) Receivables (2013 - 2026)

Akebia Therapeutics (AKBA) has 14 years of Receivables data on file, last reported at $62.8 million in Q1 2026.

• Receivables for Q1 2026 came in at $62.8 million, changed 0.42% year-over-year; the trailing twelve-month figure through Mar 2026 was $62.8 million (changed 0.42% YoY), and the FY2025 annual result was $47.2 million, up 37.41% from the prior year.
• Receivables climbed to $62.8 million in Q1 2026 per AKBA's latest filing, from $47.2 million in the prior quarter.
• Over five years, Receivables peaked at $138.6 million in Q2 2022 and troughed at $18.7 million in Q1 2023.
• A 5-year average of $48.6 million and a median of $41.1 million in 2022 frame the typical range for Receivables.
• The sharpest annual moves came in 2022 and 2023: Receivables surged 275.4% in 2022, then sank 85.5% in 2023.
• A 5-year view of Receivables shows it stood at $41.1 million in 2022, then advanced by 3.79% to $42.6 million in 2023, then declined by 19.37% to $34.4 million in 2024, then soared by 37.41% to $47.2 million in 2025, then surged by 33.06% to $62.8 million in 2026.
• Business Quant data shows AKBA's Receivables at $62.8 million in Q1 2026, $47.2 million in Q4 2025, and $66.2 million in Q3 2025.